- Home
- ATRC vs MDXG Comparison
ATRC vs MDXG Comparison
Compare ATRC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- MDXG
- Stock Information
- Founded
- ATRC 2000
- MDXG 2006
- Country
- ATRC United States
- MDXG United States
- Employees
- ATRC N/A
- MDXG N/A
- Industry
- ATRC Medical/Dental Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- MDXG Health Care
- Exchange
- ATRC Nasdaq
- MDXG Nasdaq
- Market Cap
- ATRC 1.6B
- MDXG 877.4M
- IPO Year
- ATRC 2005
- MDXG N/A
- Fundamental
- Price
- ATRC $30.72
- MDXG $6.67
- Analyst Decision
- ATRC Strong Buy
- MDXG Strong Buy
- Analyst Count
- ATRC 10
- MDXG 2
- Target Price
- ATRC $49.50
- MDXG $12.50
- AVG Volume (30 Days)
- ATRC 404.1K
- MDXG 774.6K
- Earning Date
- ATRC 07-29-2025
- MDXG 07-30-2025
- Dividend Yield
- ATRC N/A
- MDXG N/A
- EPS Growth
- ATRC N/A
- MDXG N/A
- EPS
- ATRC N/A
- MDXG 0.27
- Revenue
- ATRC $480,076,000.00
- MDXG $352,375,000.00
- Revenue This Year
- ATRC $14.63
- MDXG $9.55
- Revenue Next Year
- ATRC $12.62
- MDXG $11.43
- P/E Ratio
- ATRC N/A
- MDXG $24.67
- Revenue Growth
- ATRC 15.79
- MDXG 5.34
- 52 Week Low
- ATRC $20.20
- MDXG $5.47
- 52 Week High
- ATRC $43.11
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ATRC 39.22
- MDXG 57.60
- Support Level
- ATRC $31.00
- MDXG $5.86
- Resistance Level
- ATRC $32.44
- MDXG $7.05
- Average True Range (ATR)
- ATRC 1.03
- MDXG 0.24
- MACD
- ATRC -0.09
- MDXG 0.11
- Stochastic Oscillator
- ATRC 8.65
- MDXG 69.20
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.